Dr C Michael M Gibson (Beth Israel Deaconess Medical Center, Boston, MA, US) discusses the Angelmed for early recognition and treatment of STEMI (ALERTS) trail.
Filmed on site at CRT 2019 by Radcliffe Cardiology
1. What is the rationale for this study?
2. What was the design, number of patients enrolled and study endpoints?
3. What should this mean for clinical practice and subsequent future research?
4. What implications should this data have for clinical practice and future research?
Videographer: Tom Green
Education Lead: Liam O'Neill